Literature DB >> 27390149

Incidence of Chronic Persistent Rheumatoid Arthritis and the Impact of Smoking: A Historical Twin Cohort Study.

Anders J Svendsen1, Peter Junker2, Gunnar Houen3, Kirsten O Kyvik4, Christian Nielsen2, Axel Skytthe1, René Holst5.   

Abstract

OBJECTIVE: To assess the incidence of chronic persistent rheumatoid arthritis (RA) in a population-based cohort of twins and to determine the impact of smoking.
METHODS: In a historical cohort study on twins born in 1920 to 1982, we identified 157 cases of RA among 45,280 responders (response rate 80%). Information on smoking was obtained by questionnaire and interview. A mixed-effects Poisson regression model was used to estimate incidence rate ratios with age, sex, smoking duration, and smoking intensity as covariates. We used the SplitLexis procedure in the Epi R package to study a possible effect of period or cohort in addition to age on the variation of the incidence.
RESULTS: The annual incidence of chronic persistent RA was 18.8 per 100,000 person-years, ages 15-73 years (females 25.2, males 12.0), increasing with age to a maximum at age 60 years in females and age 70 years in males. The incidence rate ratio among ever-smoking patients was 1.96 (95% confidence interval [95% CI] 1.43-3.76), 1.93 (95% CI 1.00-3.7) after 30 pack-years, and 1.034 (P < 0.001) per year of smoking, implying a doubling of risk after 20 years regardless of sex and smoking intensity. We did not detect significant period or cohort effects.
CONCLUSION: The incidence of chronic persistent RA is lower than the incidence figures reported in inception cohorts. Smoking duration, but not intensity, doubled the risk of RA after 20 years of smoking in both sexes.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 27390149     DOI: 10.1002/acr.22987

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

Review 1.  Genetic and environmental risk factors for rheumatoid arthritis.

Authors:  Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-09-18       Impact factor: 4.098

2.  The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial.

Authors:  Ida Kristiane Roelsgaard; Thordis Thomsen; Mikkel Østergaard; Robin Christensen; Merete Lund Hetland; Søren Jacobsen; Lena Andersen; Hanne Tønnesen; Silvia Rollefstad; Anne Grete Semb; Bente Appel Esbensen
Journal:  Trials       Date:  2017-11-28       Impact factor: 2.279

Review 3.  Asthma and the Risk of Rheumatoid Arthritis: An Insight into the Heterogeneity and Phenotypes of Asthma.

Authors:  Mary Claire Rolfes; Young Jun Juhn; Chung-Il Wi; Youn Ho Sheen
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31

4.  Association between Rheumatoid Arthritis and Respiratory Allergic Diseases in Korean Adults: A Propensity Score Matched Case-Control Study.

Authors:  Han Eol Jeong; Sung-Mok Jung; Sung-Il Cho
Journal:  Int J Rheumatol       Date:  2018-04-23

Review 5.  Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians.

Authors:  Elisabeth Bendstrup; Janne Møller; Sissel Kronborg-White; Thomas Skovhus Prior; Charlotte Hyldgaard
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

6.  Rheumatoid Arthritis Interstitial Lung Disease: Measuring and Predictive Factors Among Patients Treated in Rehabilitation Clinics at Royal Medical Services.

Authors:  Deifallah Mohammad Alsharari; Laith Abdulsalam Obeidat; Hayat Khuzai Khasawneh; Moh'd Rami Hani Alhmar; Raja Mohammad Khasawneh; Zeyad Sulieman Bataineh; Ahmad Abdelqader Aldhoun
Journal:  Med Arch       Date:  2020-12

Review 7.  Etiologies of Rheumatoid Arthritis: Update on Mucosal, Genetic, and Cellular Pathogenesis.

Authors:  Vanessa L Kronzer; John M Davis
Journal:  Curr Rheumatol Rep       Date:  2021-03-01       Impact factor: 4.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.